The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 5, 2015, Pages 818-824

  Zhang, J ^a   Yin, X J ^b   Xu, C J ^a   Ning, Y X ^a   Chen, M ^a   Zhang, H ^a   Chen, S F ^a   Yao, L Q ^a  

^a FUDAN UNIVERSITY   (China)

^b Second People's Hospital of Kunshan City   (China)

Author keywords

Notch 3; Ovarian cancer; Proliferation; SIRT6

Indexed keywords

MESSENGER RNA; NOTCH3 RECEPTOR; SIRTUIN 6; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; SIRT6 PROTEIN, HUMAN; SIRTUIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; APOPTOSIS; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, NOTCH; RNA, MESSENGER; SIRTUINS;

EID: 84942246592     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. SIEGEL R, MA J, ZOU Z, JEMAL A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. KURMAN RJ, SHIH I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
3. ARMSTRONG DK, BUNDY B, WENZEL L, HUANG HQ, BAERGEN R, LELE S, COPELAND LJ, WALKER JL, BURGER RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
4. KONNER JA, GRABON DM, GERST SR, IASONOS A, THALER H, PEZZULLI SD. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 2011;29:4662-4668.
5. COOKE SL, BRENTON JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011;12:1169-1174.
6. PINATO DJ, GRAHAM J, GABRA H, SHARMA R. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev 2013;39:153-160.
7. LOWE KA, CHIA VM, TAYLOR A, O'MALLEY C, KELSH M, Mohamed M, Mowat FS, Goff B. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:107-114.
8. FINKEL T, DENG CX, MOSTOSLAVSKY R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587-591.
9. HSU CP, OKA S, SHAO D, HARIHARAN N, SADOSHIMA J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res 2009;105:481-491.
10. CORNELIUS C, TROVATO SA, SCUTO M, BELLA R, MILONE P, GRAZIANO A, CRUPI R. Cellular stress response, sirtuins and UCP proteins in Alzheimer disease: role of vitagenes. Immun Ageing 2013;10:41-48.
11. CARAFA V, NEBBIOSO A, ALTUCCI L. Sirtuins and disease: the road ahead. Front Pharmacol 2012;3:4-10.
12. GUARENTE L. The many faces of sirtuins: Sirtuins and the Warburg effect. Nat Med 2014;20:24-25.
13. BOSCH-PRESEGUE L, VAQUERO A. The dual role of sirtuins in cancer. Genes Cancer 2011;2:648-662.
14. MOSTOSLAVSKY R, CHUA KF, LOMBARD DB, PANG WW, GELLON L, LIU P, MOSTOSLAVSKY G, FRANCO S, BARRETT JC, DEMPLE B, YANCOPOULOS GD, ALT FW. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-329.
15. ZHONG L, D'URSO A, TOIBER D, NIR T, CLISH CB, VAITHEESVARAN B, ILIOPOULOS O, KURLAND I, ESPINOSA JM. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010;140:280-293.
16. MARQUARDT JU, FISCHER K, BAUS K, KASHYAP A, MA S, KRUPP M, LINKE M, TEUFEL A, ZECHNER U. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013;58:1054-1064.
17. SEBASTIAN C, ZWAANS BM, SILBERMAN DM, GYMREK M, GOREN A, ZHONG L, RAM O, TRUELOVE J, MAXWELL F, MOSTOSLAVSKY R. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012;151:1185-1199.
18. KHONGKOW M, OLMOS Y, GONG C, GOMES AR, MONTEIRO LJ, YAGUE E, CAVACO TB, KHONGKOW P, LAM EW. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 2013;34:1476-1486.
19. ZHANG P, TU B, TANG M, ZHANG C, GU B, LI Z, WANG L, YANG Y, ZHU WG. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc Natl Acad Sci U S A 2014;111:10684-10689.
20. MARTINEZ-PASTOR B, MOSTOSLAVSKY R. Sirtuins, metabolism, and cancer. Front Pharmacol 2012;3:22-28.
21. JASPER H. Sirtuins: Longevity focuses on NAD+. Nat Chem Biol 2013;9:666-667.
22. CHEN X, HAO B, LIU Y, DAI D, HAN G, LI Y, WU X, ZHOU X, YUE Z, WANG L, CAO Y, LIU J. The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma. Biochem Biophys Res Commun 2014;446:364-369.
23. MIN L, JI Y, BAKIRI L, QIU Z, CEN J, CHEN X, CHEN L, SCHEUCH H, ZHENG H, QIN L, ZATLOUKAL K, HUI L, WAGNER EF. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012;14:1203-1211.
24. VAN METER M, MAO Z, GORBUNOVA V, SELUANOV A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011;10:3153-3158.
25. RIZZO P, OSIPO C, FOREMAN K, GOLDE T, OSBORNE B, MIELE L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-5131.
26. CHEN J, KESARI S, ROONEY C, STRACK PR, CHEN J, SHEN H, WU L, GRIFFIN JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010;1:822-835.
27. GE W, REN J. mTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism. J Cell Mol Med 2012;16:616-626.
28. ROSE SL. Notch signaling pathway in ovarian cancer. Int J Gynecol Cancer 2009;19:564-566.
29. AL-HUSSAINI H, SUBRAMANYAM D, REEDIJK M, SRIDHAR SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011;10:9-15.
30. LU KH, PATTERSON AP, WANG L, MARQUEZ RT, BAGGERLY KA, WHITAKER R, GERSHENSON DM, MILLS GB, BAST RJ. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-3300.
31. JUNG SG, KWON YD, SONG JA, BACK MJ, LEE SY, LEE C, HWANG YY, AN HJ. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci 2010;101:1977-1983.